Published in Nucleic Acids Res on April 25, 1993
Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res (2010) 3.71
Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease. Mol Nutr Food Res (2008) 2.23
Proteolytic degradation of MAD3 (I kappa B alpha) and enhanced processing of the NF-kappa B precursor p105 are obligatory steps in the activation of NF-kappa B. Nucleic Acids Res (1993) 2.08
Inhibition of NF-kappaB DNA binding by nitric oxide. Nucleic Acids Res (1996) 1.94
The PEST-like sequence of I kappa B alpha is responsible for inhibition of DNA binding but not for cytoplasmic retention of c-Rel or RelA homodimers. Mol Cell Biol (1995) 1.64
Functional interference of Sp1 and NF-kappaB through the same DNA binding site. Mol Cell Biol (1998) 1.60
Domain organization of I kappa B alpha and sites of interaction with NF-kappa B p65. Mol Cell Biol (1995) 1.44
Redox sensing: orthogonal control in cell cycle and apoptosis signalling. J Intern Med (2010) 1.24
Inducible degradation of I kappa B alpha in vitro and in vivo requires the acidic C-terminal domain of the protein. Mol Cell Biol (1995) 1.24
A new APE1/Ref-1-dependent pathway leading to reduction of NF-kappaB and AP-1, and activation of their DNA-binding activity. Nucleic Acids Res (2008) 1.22
The Arabidopsis thaliana apurinic endonuclease Arp reduces human transcription factors Fos and Jun. Proc Natl Acad Sci U S A (1994) 1.17
Two alleles of NF-kappaB in the sea anemone Nematostella vectensis are widely dispersed in nature and encode proteins with distinct activities. PLoS One (2009) 1.12
Interaction of the C-terminal region of p105 with the nuclear localisation signal of p50 is required for inhibition of NF-kappa B DNA binding activity. Nucleic Acids Res (1993) 1.07
Reactive oxygen species, nutrition, hypoxia and diseases: Problems solved? Redox Biol (2015) 1.02
Creating PWMs of transcription factors using 3D structure-based computation of protein-DNA free binding energies. BMC Bioinformatics (2010) 1.00
Domain organization of the adenovirus preterminal protein. J Virol (1997) 0.99
The transcription factor NF-kappaB in the demosponge Amphimedon queenslandica: insights on the evolutionary origin of the Rel homology domain. Dev Genes Evol (2008) 0.96
Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma. Free Radic Biol Med (2014) 0.94
Nrf2 and NF-κB and Their Concerted Modulation in Cancer Pathogenesis and Progression. Cancers (Basel) (2010) 0.94
Temperature-sensitive transforming mutants of the v-rel oncogene. J Virol (1993) 0.86
Nutritional countermeasures targeting reactive oxygen species in cancer: from mechanisms to biomarkers and clinical evidence. Antioxid Redox Signal (2013) 0.86
Increased inflammatory signaling and lethality of influenza H1N1 by nuclear thioredoxin-1. PLoS One (2011) 0.85
Conformational changes induced by DNA binding of NF-kappa B. Nucleic Acids Res (1995) 0.83
DNA binding alters the protease susceptibility of the p50 subunit of NF-kappa B. Nucleic Acids Res (1993) 0.82
The conserved redox-sensitive cysteine residue of the DNA-binding region in the c-Rel protein is involved in the regulation of the phosphorylation of the protein. Biochem J (2000) 0.81
The glutathione synthesis gene Gclm modulates amphiphilic polymer-coated CdSe/ZnS quantum dot-induced lung inflammation in mice. PLoS One (2013) 0.80
I(kappa)B(gamma) inhibits DNA binding of NF-kappaB p50 homodimers by interacting with residues that contact DNA. Mol Cell Biol (1996) 0.78
A mutant v-rel with increased ability to transform B lymphocytes. J Virol (1995) 0.78
Lipophilic compound-mediated gene expression and implication for intervention in reactive oxygen species (ROS)-related diseases: mini-review. Nutrients (2010) 0.77
Iso-seco-tanapartholides: Isolation, Synthesis and Biological Evaluation. European J Org Chem (2009) 0.77
Identification and validation of p50 as the cellular target of eriocalyxin B. Oncotarget (2014) 0.77
Piperlongumine inhibits lung tumor growth via inhibition of nuclear factor kappa B signaling pathway. Sci Rep (2016) 0.76
Characterization of a novel curcumin analog P1 as potent inhibitor of the NF-κB signaling pathway with distinct mechanisms. Acta Pharmacol Sin (2013) 0.75
Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene (1989) 60.30
Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene (1988) 52.71
The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product. Cell (1990) 9.37
Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal. Cell (1990) 9.24
The inducible transcription activator NF-kappa B: regulation by distinct protein subunits. Biochim Biophys Acta (1991) 7.70
Redox regulation of fos and jun DNA-binding activity in vitro. Science (1990) 7.09
DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide. Cell (1991) 6.63
Hydrogen bonding and biological specificity analysed by protein engineering. Nature (1985) 6.20
The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell (1992) 5.85
A 65-kappaD subunit of active NF-kappaB is required for inhibition of NF-kappaB by I kappaB. Genes Dev (1989) 5.61
Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B. Science (1991) 5.52
Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J (1992) 5.23
Cloning of an NF-kappa B subunit which stimulates HIV transcription in synergy with p65. Nature (1991) 5.07
Identification and purification of a human immunoglobulin-enhancer-binding protein (NF-kappa B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro. Proc Natl Acad Sci U S A (1988) 4.33
Nucleic acid sequences of the oncogene v-rel in reticuloendotheliosis virus strain T and its cellular homolog, the proto-oncogene c-rel. J Virol (1984) 4.17
RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B. Mol Cell Biol (1992) 4.03
The graded distribution of the dorsal morphogen is initiated by selective nuclear transport in Drosophila. Cell (1989) 3.77
Dorsal, an embryonic polarity gene in Drosophila, is homologous to the vertebrate proto-oncogene, c-rel. Science (1987) 3.74
A novel mitogen-inducible gene product related to p50/p105-NF-kappa B participates in transactivation through a kappa B site. Mol Cell Biol (1992) 3.63
Independent modes of transcriptional activation by the p50 and p65 subunits of NF-kappa B. Genes Dev (1992) 3.47
NF-kappa B contacts DNA by a heterodimer of the p50 and p65 subunit. EMBO J (1991) 3.28
Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res (1992) 3.22
Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci U S A (1991) 3.07
The 65-kD subunit of NF-kappa B is a receptor for I kappa B and a modulator of DNA-binding specificity. Genes Dev (1990) 2.98
DNA binding of purified transcription factor NF-kappa B. Affinity, specificity, Zn2+ dependence, and differential half-site recognition. J Biol Chem (1991) 2.80
The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain. Mol Cell Biol (1990) 2.47
Site-directed mutagenesis as a probe of enzyme structure and catalysis: tyrosyl-tRNA synthetase cysteine-35 to glycine-35 mutation. Biochemistry (1983) 2.31
Transcriptional regulation of the HIV-1 promoter by NF-kappa B in vitro. Genes Dev (1992) 2.12
Casein kinase II phosphorylation increases the rate of serum response factor-binding site exchange. EMBO J (1992) 1.60
Structure of a mammalian c-rel protein deduced from the nucleotide sequence of murine cDNA clones. Oncogene Res (1989) 1.41
Interaction of enhancer-binding protein EBP1 (NF-kappa B) with the human immunodeficiency virus type 1 enhancer. J Virol (1990) 1.22
Enhancer binding protein (EBP1) makes base and backbone contacts over one complete turn of the DNA double helix. J Mol Biol (1989) 1.19
Expression of a mRNA related to c-rel and dorsal in early Xenopus laevis embryos. Proc Natl Acad Sci U S A (1991) 1.07
SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell (1998) 6.62
CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell (1996) 6.52
Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem (2001) 5.04
SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem (2000) 4.96
Initiation of SV40 DNA replication in vivo: location and structure of 5' ends of DNA synthesized in the ori region. Cell (1982) 4.50
SUMO-1 modification activates the transcriptional response of p53. EMBO J (1999) 4.19
Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science (1997) 3.84
Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res (1992) 3.22
Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry (1999) 3.07
The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med (1998) 2.94
Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry (1997) 2.87
Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med (1998) 2.76
Ubch9 conjugates SUMO but not ubiquitin. FEBS Lett (1997) 2.73
Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol (2000) 2.72
Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NF-kappa B. Mol Cell Biol (1995) 2.69
A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science (1997) 2.58
Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem (1996) 2.56
SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci (1999) 2.46
Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci (1997) 2.44
Molecular cloning and functional expression of a novel CC chemokine receptor cDNA from a human basophilic cell line. J Biol Chem (1995) 2.38
An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene (2000) 2.36
Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J Cell Biol (1997) 2.35
Dendritic cells are recruited into the airway epithelium during the inflammatory response to a broad spectrum of stimuli. J Exp Med (1996) 2.19
Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J Biol Chem (1999) 2.18
A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock. J Exp Med (2000) 2.17
Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. EMBO J (1995) 2.10
Proteolytic degradation of MAD3 (I kappa B alpha) and enhanced processing of the NF-kappa B precursor p105 are obligatory steps in the activation of NF-kappa B. Nucleic Acids Res (1993) 2.08
Nuclear retention of IkappaBalpha protects it from signal-induced degradation and inhibits nuclear factor kappaB transcriptional activation. J Biol Chem (1999) 2.05
Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol (1997) 2.02
Cooperativity between two NF-kappa B complexes, mediated by high-mobility-group protein I(Y), is essential for cytokine-induced expression of the E-selectin promoter. Mol Cell Biol (1994) 1.98
Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytes. J Exp Med (1997) 1.97
zeta PKC induces phosphorylation and inactivation of I kappa B-alpha in vitro. EMBO J (1994) 1.95
Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat Med (1999) 1.94
Inhibition of NF-kappaB DNA binding by nitric oxide. Nucleic Acids Res (1996) 1.94
Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene (1999) 1.93
The origin of adenovirus DNA replication: minimal DNA sequence requirement in vivo. EMBO J (1985) 1.89
The adenovirus protease is activated by a virus-coded disulphide-linked peptide. Cell (1993) 1.86
Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo. J Biol Chem (1996) 1.82
Properties of herpesvirus-induced "immediate early" polypeptides. Virology (1980) 1.75
The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem (2000) 1.73
Solid phase DNA amplification: characterisation of primer attachment and amplification mechanisms. Nucleic Acids Res (2000) 1.73
Identification of a glycosaminoglycan binding surface on human interleukin-8. Biochemistry (1998) 1.71
Structure-activity relationships in engineered proteins: analysis of use of binding energy by linear free energy relationships. Biochemistry (1987) 1.69
HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci U S A (1998) 1.67
A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature (1993) 1.64
Rat ATP citrate-lyase. Molecular cloning and sequence analysis of a full-length cDNA and mRNA abundance as a function of diet, organ, and age. J Biol Chem (1990) 1.64
Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3alpha from lung dendritic cells. J Exp Med (1997) 1.63
Replication of adenovirus mini-chromosomes. J Mol Biol (1984) 1.62
Kinetics of eotaxin generation and its relationship to eosinophil accumulation in allergic airways disease: analysis in a guinea pig model in vivo. J Exp Med (1997) 1.61
Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J Exp Med (1998) 1.58
Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J Gen Virol (1992) 1.57
The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors. J Biol Chem (1999) 1.55
Recognition of the adenovirus type 2 origin of DNA replication by the virally encoded DNA polymerase and preterminal proteins. EMBO J (1992) 1.52
The Swiss-3DImage collection and PDB-Browser on the World-Wide Web. Trends Biochem Sci (1995) 1.44
Domain organization of I kappa B alpha and sites of interaction with NF-kappa B p65. Mol Cell Biol (1995) 1.44
Eotaxin: cloning of an eosinophil chemoattractant cytokine and increased mRNA expression in allergen-challenged guinea-pig lungs. Biochem Biophys Res Commun (1994) 1.43
The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood (1998) 1.42
Chemokine receptors--the next therapeutic target for HIV? Receptors Channels (2001) 1.42
Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett (1997) 1.41
Platelet activation and signal transduction by convulxin, a C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor. J Biol Chem (1997) 1.40
The adenovirus type 40 hexon: sequence, predicted structure and relationship to other adenovirus hexons. J Gen Virol (1989) 1.39
Platelet glycoprotein Ia* is the processed form of multimerin--isolation and determination of N-terminal sequences of stored and released forms. Thromb Haemost (1998) 1.39
Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-gamma in human neutrophils. J Immunol (1999) 1.37
Activation of NF-kappaB by PM(10) occurs via an iron-mediated mechanism in the absence of IkappaB degradation. Toxicol Appl Pharmacol (2000) 1.36
DNA sequence of the adenovirus type 41 hexon gene and predicted structure of the protein. J Gen Virol (1988) 1.36
p75-mediated NF-kappaB activation enhances the survival response of developing sensory neurons to nerve growth factor. Mol Cell Neurosci (1999) 1.34
Use of binding energy in catalysis analyzed by mutagenesis of the tyrosyl-tRNA synthetase. Biochemistry (1986) 1.34
Interactions between the adenovirus type 2 DNA polymerase and the DNA binding domain of nuclear factor I. New Biol (1990) 1.33
Identification of lysine residues required for signal-induced ubiquitination and degradation of I kappa B-alpha in vivo. Oncogene (1996) 1.30
Common properties of nuclear body protein SP100 and TIF1alpha chromatin factor: role of SUMO modification. Mol Cell Biol (2001) 1.29
Sequence requirement for specific interaction of an enhancer binding protein (EBP1) with DNA. Nucleic Acids Res (1989) 1.29
Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J (1999) 1.28
Co-operative interactions between NFI and the adenovirus DNA binding protein at the adenovirus origin of replication. EMBO J (1989) 1.28
The x-ray crystal structure of phosphomannose isomerase from Candida albicans at 1.7 angstrom resolution. Nat Struct Biol (1996) 1.27
Identification and purification of EBP1: a HeLa cell protein that binds to a region overlapping the 'core' of the SV40 enhancer. Genes Dev (1988) 1.27
Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin. J Clin Invest (1997) 1.27
Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol (1994) 1.25
NF-kappaB inhibits apoptosis in murine mammary epithelia. J Biol Chem (2000) 1.25
Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood (2000) 1.24
Inducible degradation of I kappa B alpha in vitro and in vivo requires the acidic C-terminal domain of the protein. Mol Cell Biol (1995) 1.24
Interaction of enhancer-binding protein EBP1 (NF-kappa B) with the human immunodeficiency virus type 1 enhancer. J Virol (1990) 1.22
Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J Biol Chem (1999) 1.22
Sequence specificity for the initiation of RNA-primed simian virus 40 DNA synthesis in vivo. J Mol Biol (1984) 1.22
Origin of adenovirus DNA replication. Role of the nuclear factor I binding site in vivo. J Mol Biol (1985) 1.21
Similarities and differences in RANTES- and (AOP)-RANTES-triggered signals: implications for chemotaxis. J Cell Biol (1999) 1.20
The three-dimensional solution structure of RANTES. Biochemistry (1995) 1.20
Characterization of IkappaBalpha nuclear import pathway. J Biol Chem (1999) 1.20
Enhancer binding protein (EBP1) makes base and backbone contacts over one complete turn of the DNA double helix. J Mol Biol (1989) 1.19
NF-kappa B-dependent induction of the NF-kappa B p50 subunit gene promoter underlies self-perpetuation of human immunodeficiency virus transcription in monocytic cells. Proc Natl Acad Sci U S A (1992) 1.18
Regulation of dendritic cell recruitment into resting and inflamed airway epithelium: use of alternative chemokine receptors as a function of inducing stimulus. J Immunol (2001) 1.16
Nuclear factor I is specifically targeted to discrete subnuclear sites in adenovirus type 2-infected cells. J Virol (1992) 1.15
Regulation of transcription factors by protein degradation. Cell Mol Life Sci (2000) 1.15
SUMO modification of the DEAD box protein p68 modulates its transcriptional activity and promotes its interaction with HDAC1. Oncogene (2007) 1.14
Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Oncogene (1998) 1.14
Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein. J Virol (1997) 1.13
Molecular cloning of murine CC CKR-4 and high affinity binding of chemokines to murine and human CC CKR-4. Biochem Biophys Res Commun (1996) 1.13
Receptor-mediated endocytosis of CC-chemokines. J Biol Chem (1997) 1.12
Chemokine and chemokine receptor mRNA expression in human platelets. Cytokine (1995) 1.10